FDA Will Face Reforms, Oversight In Republican Congress – Analysts
This article was originally published in The Rose Sheet
Executive Summary
Election gains will embolden Republicans to put FDA in Congress’ oversight “crosshairs,” as members of key Senate and House panels scrutinize how the agency is using its resources. Reforms also could come soon as part of the ongoing 21st Century Cures initiative.
You may also be interested in...
IRB, HIPAA Changes To Be Folded Into 21st Century Cures Bill Next Year
Centralized institutional review board approvals for device trials, and removal of HIPAA privacy provisions that block registry data-sharing are among the ideas that are likely to make it into a draft bill planned for release in January as the next step in the House’s 21st Century Cures initiative.
Shuren Highlights CDRH Actions To Ease Trial Burdens On Capitol Hill
CDRH Director Jeffrey Shuren participated in the first roundtable of a newly launched House Energy and Commerce Committee initiative to accelerate drug and device development. He emphasized the device center’s recent proposals to minimize pre-market data collection with postmarket controls, and supported the promise of clinical trial networks.
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.